Fastest-Growing Companies

America's fastest growing companies ranked by stock growth and state.

1 of 100
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Financials: Latest Results
Rank: 1
3-year average
Revenue Growth: 68%
Profit Growth: 279%
Total Return: 106%

In medical terminology, a bolus is a massive dose of a drug administered all at once. Jazz Pharmaceuticals has experienced a similar infusion of cash recently, thanks in large part to the success of its narcolepsy drug, Xyrem, which improves the quality of narcoleptics’ waking hours by helping them get a good night’s sleep.

With no market competition for Xyrem, the Dublin-based biopharmaceutical has been able to ratchet up its price twice this year. Acquisitions of Azur Pharma and EUSA Pharma in 2012 are also adding sales and reducing the company’s reliance on Xyrem. With EUSA, Jazz brought in Erwinaze, now the second-highest seller in its ensemble. The leukemia drug contributed more than 20% of the company’s first quarter revenue. --Shannon Green

Revenues ($ millions): 680
Net Income ($ millions): 304.3
Sector: Health Care
What businesses do you think are primed to grow in this economy?
To qualify, a company-domestic or foreign-must be trading on a major U.S. stock exchange; report data in U.S. dollars; file quarterly reports with the SEC; have a minimum market... More
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.